The liberation treatment announced by Paolo Zamboni in 2009 for treating patients who have multiple sclerosis raised a ray of hope for many. But the effectiveness of the therapy has been questioned by a recent research.

The study conducted by the Canadian Institutes of Health Research and the MS Society of Canada, which was published on August 31 analyzed the biological theory related to Cerebrospinal Venous Insufficiency (CCSVI) and the clinical process employed in the liberation treatment.

The report brought out that there are faults with the procedure discovered by Dr. Zamboni and cautioned it to be carried out on pilot basis only. The liberation treatment follows an intervention, venous angioplasty that is detrimental and leads to stroke and heart problems.

In a nut shell, the report termed the liberation treatment as ineffective and stressed on the need for more research on the CCSVI theory.

Leona Aglukkaq, Federal Health Minister said, “I intend to follow the recommendations of the report and not devote federal money to clinical trials at this time”.

But provinces like Saskatchewan, Newfoundland and Labrador will be financing the trials for liberation treatment. The report included that any funding into the MS’ liberation treatment would raise some more questions regarding the use of public resources in such researches, if trials on MS patients are ethically sound or not and the availability of the treatment at heavy prices by the Government.